ZA9410096B - Methods of inhibiting myeloperoxidase activity - Google Patents

Methods of inhibiting myeloperoxidase activity

Info

Publication number
ZA9410096B
ZA9410096B ZA9410096A ZA9410096A ZA9410096B ZA 9410096 B ZA9410096 B ZA 9410096B ZA 9410096 A ZA9410096 A ZA 9410096A ZA 9410096 A ZA9410096 A ZA 9410096A ZA 9410096 B ZA9410096 B ZA 9410096B
Authority
ZA
South Africa
Prior art keywords
methods
myeloperoxidase activity
inhibiting myeloperoxidase
inhibiting
activity
Prior art date
Application number
ZA9410096A
Other languages
English (en)
Inventor
Andrew Lawrence Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA9410096B publication Critical patent/ZA9410096B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9410096A 1993-12-21 1994-12-19 Methods of inhibiting myeloperoxidase activity ZA9410096B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,330 US5708009A (en) 1993-12-21 1993-12-21 Methods of inhibiting myeloperoxidase activity

Publications (1)

Publication Number Publication Date
ZA9410096B true ZA9410096B (en) 1996-06-19

Family

ID=22623358

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9410096A ZA9410096B (en) 1993-12-21 1994-12-19 Methods of inhibiting myeloperoxidase activity

Country Status (16)

Country Link
US (2) US5708009A (de)
EP (1) EP0664125A1 (de)
JP (1) JPH07242546A (de)
KR (1) KR950016743A (de)
CN (1) CN1109884A (de)
AU (1) AU8154394A (de)
CA (1) CA2138513A1 (de)
CZ (1) CZ322794A3 (de)
HU (1) HUT72314A (de)
IL (1) IL112047A0 (de)
NO (1) NO944926L (de)
NZ (1) NZ270184A (de)
PH (1) PH31556A (de)
RU (1) RU94044489A (de)
TW (1) TW272939B (de)
ZA (1) ZA9410096B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
HUP9801829A3 (en) * 1995-02-06 1999-10-28 Lilly Co Eli Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
EP1175433B1 (de) 1999-05-04 2005-08-03 Strakan International Limited Androgen glykoside und die androgenische aktivität davon
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
AU2004204675A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
ATE465172T1 (de) * 2004-03-05 2010-05-15 Univ Illinois Peptidträger für die verabreichung von arzneimitteln
EP2010534A4 (de) * 2006-04-13 2010-08-18 Astrazeneca Ab Thioxanthinderivate und ihre verwendung als mpo-inhibitoren
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use

Also Published As

Publication number Publication date
HUT72314A (en) 1996-04-29
HU9403677D0 (en) 1995-02-28
PH31556A (en) 1998-11-03
NO944926L (no) 1995-06-22
CZ322794A3 (en) 1995-08-16
NZ270184A (en) 1999-07-29
NO944926D0 (no) 1994-12-19
US5708009A (en) 1998-01-13
US5708010A (en) 1998-01-13
RU94044489A (ru) 1996-10-20
EP0664125A1 (de) 1995-07-26
AU8154394A (en) 1995-06-29
CN1109884A (zh) 1995-10-11
CA2138513A1 (en) 1995-06-22
KR950016743A (ko) 1995-07-20
JPH07242546A (ja) 1995-09-19
IL112047A0 (en) 1995-03-15
TW272939B (de) 1996-03-21

Similar Documents

Publication Publication Date Title
AU115932S (en) Ear-ring
ZA945426B (en) Treatment of tachyarrhytmias of supraventricular origin
HK1018570A1 (en) Retaining construction of watchband
HU9403677D0 (en) Methods of inhibiting myeloperoxidase activity
HU9702242D0 (en) Inozitol-glykanes of inzulin-like activity
IL112031A0 (en) Methods of inhibiting autoimmune diseases
GB2272394B (en) Scalpel
PL332904A1 (en) Dihydropyrones of improved antiviral activity
AU116125S (en) Wristwatch
GB9216582D0 (en) Determination of enzyme activity
GB2284739B (en) Processing of whelks
GB9317943D0 (en) Treatment of laminitis
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9317989D0 (en) Treatment of laminitis
PL55382Y1 (en) Set of symmetrisers
DE69305964D1 (en) Etherimidimid/etherimid copolymere
GB9212535D0 (en) Treatment of boimass
GB2304588B (en) Activity equipment
GB9224395D0 (en) Kango jump
PL295703A1 (en) Reactor
GB9202770D0 (en) Enzymatic treatment
GB9211272D0 (en) Treatment of catalysts
GB9216142D0 (en) Natural compounds having biological activity
IL106989A0 (en) Distribution of software
GB9216394D0 (en) Ear-ring